These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
798 related articles for article (PubMed ID: 19036441)
1. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1. Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441 [TBL] [Abstract][Full Text] [Related]
2. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Stege A; Priebsch A; Nieth C; Lage H Cancer Gene Ther; 2004 Nov; 11(11):699-706. PubMed ID: 15375376 [TBL] [Abstract][Full Text] [Related]
3. The reversion effect of the RNAi-silencing mdr1 gene on multidrug resistance of the leukemia cell HT9. Shao SL; Sun YY; Li XY; Zhang WW; Fu B; Yun DZ; Zuo MX Cell Biol Int; 2008 Aug; 32(8):893-8. PubMed ID: 18499486 [TBL] [Abstract][Full Text] [Related]
4. Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors. Gan HZ; Zhang GZ; Zhao JS; Zhang FC; Bu LS; Yang SJ; Piao SL; Du ZW; Gao S; Zheng DM Chin Med J (Engl); 2005 Jun; 118(11):893-902. PubMed ID: 15978189 [TBL] [Abstract][Full Text] [Related]
5. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833 [TBL] [Abstract][Full Text] [Related]
6. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1. Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188 [TBL] [Abstract][Full Text] [Related]
7. [Reversal of multi-drug resistance in K562/A02 cells by small interference RNA of mdr1 gene]. Peng Z; Xiao ZJ; Wang Y; Liu P; Cai YL; Feng WL; Han ZC Zhonghua Xue Ye Xue Za Zhi; 2004 Jan; 25(1):5-7. PubMed ID: 14990067 [TBL] [Abstract][Full Text] [Related]
8. [Reversal of multidrug resistance by MDR1 shRNA expression vector in human leukemia K562/A02 cells]. Xiao XB; Xie ZX; Qin Q Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):422-5. PubMed ID: 17152486 [TBL] [Abstract][Full Text] [Related]
9. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes. Kaszubiak A; Holm PS; Lage H Int J Oncol; 2007 Aug; 31(2):419-30. PubMed ID: 17611700 [TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145 [TBL] [Abstract][Full Text] [Related]
11. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236 [TBL] [Abstract][Full Text] [Related]
12. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo. Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326 [TBL] [Abstract][Full Text] [Related]
13. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Bhat UG; Winter MA; Pearce HL; Beck WT Mol Pharmacol; 1995 Oct; 48(4):682-9. PubMed ID: 7476894 [TBL] [Abstract][Full Text] [Related]
14. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells. Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039 [TBL] [Abstract][Full Text] [Related]
15. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Yagüe E; Higgins CF; Raguz S Gene Ther; 2004 Jul; 11(14):1170-4. PubMed ID: 15164094 [TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin. Yang CZ; Luan FJ; Xiong DS; Liu BR; Xu YF; Gu KS Zhongguo Yao Li Xue Bao; 1995 Jul; 16(4):333-7. PubMed ID: 7668104 [TBL] [Abstract][Full Text] [Related]
17. Modulating multidrug resistance gene in leukaemia cells by short interfering RNA. Lim MN; Lau NS; Chang KM; Leong CF; Zakaria Z Singapore Med J; 2007 Oct; 48(10):932-8. PubMed ID: 17909680 [TBL] [Abstract][Full Text] [Related]
18. Reversal of cancer multidrug resistance by green tea polyphenols. Mei Y; Qian F; Wei D; Liu J J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646 [TBL] [Abstract][Full Text] [Related]
19. Sensitization and apoptosis augmentation of K562/ADM cells by anti-multidrug resistance gene peptide nucleic acid and antisense oligodeoxyribonucleotide. Wei HL; Wu YJ; Jing T; Bai DC; Ma LF Acta Pharmacol Sin; 2003 Aug; 24(8):805-11. PubMed ID: 12904281 [TBL] [Abstract][Full Text] [Related]
20. Reversal of MDR1 gene-dependent multidrug resistance using low concentration of endonuclease-prepared small interference RNA. Li L; Xu J; Min T; Huang W Eur J Pharmacol; 2006 Apr; 536(1-2):93-7. PubMed ID: 16564522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]